FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 275 filers reported holding FATE THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.99 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $1,187,000 | -16.4% | 52,950 | -7.6% | 0.01% | -21.4% |
| Q2 2022 | $1,420,000 | -86.8% | 57,320 | -56.1% | 0.01% | -86.7% |
| Q1 2021 | $10,775,000 | -4.7% | 130,688 | +5.1% | 0.10% | -17.3% |
| Q4 2020 | $11,309,000 | +155.5% | 124,368 | +12.3% | 0.13% | +95.4% |
| Q3 2020 | $4,427,000 | +21.8% | 110,747 | +4.5% | 0.06% | +32.7% |
| Q2 2020 | $3,636,000 | +19.1% | 105,979 | -22.9% | 0.05% | +4.3% |
| Q1 2020 | $3,052,000 | +2.5% | 137,433 | -9.7% | 0.05% | +104.3% |
| Q4 2019 | $2,978,000 | +47.1% | 152,157 | +16.7% | 0.02% | +43.8% |
| Q3 2019 | $2,025,000 | -26.9% | 130,386 | -4.4% | 0.02% | -23.8% |
| Q2 2019 | $2,770,000 | +1.2% | 136,434 | -12.5% | 0.02% | +10.5% |
| Q1 2019 | $2,738,000 | +43.1% | 155,838 | +4.5% | 0.02% | +26.7% |
| Q4 2018 | $1,913,000 | +24.2% | 149,103 | +57.7% | 0.02% | +50.0% |
| Q3 2018 | $1,540,000 | +77.0% | 94,532 | +23.2% | 0.01% | +66.7% |
| Q2 2018 | $870,000 | – | 76,714 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |